Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Gastroesophageal Reflux Disease | Research

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

Authors: Hyun Lim, Jong Kyu Park, Hyunsoo Chung, Si Hyung Lee, Jae Myung Park, Jung Ho Park, Gwang Ha Kim, Sung Kwan Shin, Su Jin Hong, Kwang Jae Lee, Moo In Park, Hye-Kyung Jung, Hyun-Soo Kim, Jae Kyu Sung, Seong Woo Jeon, Suck Chei Choi, Jeong Seop Moon, Nayoung Kim, Jong-Jae Park, Sung Hee Hong, Na Young Kim, Hwoon-Yong Jung

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Proton-pump inhibitors (PPIs) are the most effective drugs for treating acid-related disorders. However, once-daily dosing with conventional PPIs fail to fully control acid secretion over 24 h. This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release esomeprazole) and HGP1705 (delayed-release esomeprazole) in patients with erosive esophagitis (EE).

Methods

We enrolled 213 patients with EE randomized in a 1:1 ratio to receive 40 mg HIP1601 (n = 107) or HGP1705 (n = 106) once daily for 4 or 8 weeks. The primary endpoint was the EE healing rate, confirmed by endoscopy up to week 8. GERD-related symptoms and treatment-emergent adverse events were compared between both groups.

Results

By week 8, the estimated healing rates of EE were 97.8% and 96.8% in the HIP1601 and HGP1705 groups, respectively, with a 95% confidence interval of -4.7 to 7.2. After 4 or 8 weeks of treatment, the EE healing rate at week 4, complete resolution rate of symptoms, time to sustained resolution of symptoms, and number of rescue medications used were similar in both groups. The proportion of heartburn- and acid regurgitation-free nights by week 4 were higher in the HIP1601 group compared to the HGP1705 group, but the difference did not reach clinical significance (87.7% vs. 85.8%, P = 0.514, 87.5% vs. 85.8%, P = 0.774). The number of adverse events did not differ significantly between the two groups.

Conclusions

The efficacy and safety of HIP1601 40 mg were comparable to those of HGP1705 40 mg for the treatment of EE and symptomatic improvement of GERD.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux Disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20. quiz 1943.CrossRefPubMed Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux Disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20. quiz 1943.CrossRefPubMed
2.
go back to reference Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux Disease– an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767–76.CrossRefPubMed Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux Disease– an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767–76.CrossRefPubMed
3.
go back to reference Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M. Psychometric validation of the Japanese translation of the quality of Life in Reflux and dyspepsia questionnaire in patients with heartburn. J Gastroenterol. 2007;42(10):807–15.CrossRefPubMed Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M. Psychometric validation of the Japanese translation of the quality of Life in Reflux and dyspepsia questionnaire in patients with heartburn. J Gastroenterol. 2007;42(10):807–15.CrossRefPubMed
4.
go back to reference Oh JH. [Health-related quality of life issues in gastroesophageal reflux Disease]. Korean J Gastroenterol = Taehan Sohwagi Hakhoe Chi. 2010;55(2):85–93.CrossRefPubMed Oh JH. [Health-related quality of life issues in gastroesophageal reflux Disease]. Korean J Gastroenterol = Taehan Sohwagi Hakhoe Chi. 2010;55(2):85–93.CrossRefPubMed
5.
go back to reference Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux Disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.CrossRefPubMed Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux Disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.CrossRefPubMed
6.
go back to reference Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of Proton Pump inhibitors: Expert Review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.CrossRefPubMed Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of Proton Pump inhibitors: Expert Review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.CrossRefPubMed
8.
go back to reference Kim HC, Yang E, Ban MS, Kim YK, Hong SH, Jung J, Jang IJ, Lee S. Pharmacokinetics and pharmacodynamics of Esomezol DR, a New Dual delayed-release formulation of Esomeprazole 20 mg or 40 mg, in healthy subjects. Drug Des Devel Ther. 2023;17:1115–24.CrossRefPubMedPubMedCentral Kim HC, Yang E, Ban MS, Kim YK, Hong SH, Jung J, Jang IJ, Lee S. Pharmacokinetics and pharmacodynamics of Esomezol DR, a New Dual delayed-release formulation of Esomeprazole 20 mg or 40 mg, in healthy subjects. Drug Des Devel Ther. 2023;17:1115–24.CrossRefPubMedPubMedCentral
9.
go back to reference Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–80.CrossRefPubMedPubMedCentral Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–80.CrossRefPubMedPubMedCentral
10.
go back to reference Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–65.CrossRefPubMed Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–65.CrossRefPubMed
11.
go back to reference Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21(6):739–46.CrossRefPubMed Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21(6):739–46.CrossRefPubMed
12.
go back to reference Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575–83.CrossRefPubMed Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575–83.CrossRefPubMed
13.
go back to reference Sontag SJ, Hirschowitz BI, Holt S, Robinson MG, Behar J, Berenson MM, McCullough A, Ippoliti AF, Richter JE, Ahtaridis G, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology. 1992;102(1):109–18.CrossRefPubMed Sontag SJ, Hirschowitz BI, Holt S, Robinson MG, Behar J, Berenson MM, McCullough A, Ippoliti AF, Richter JE, Ahtaridis G, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology. 1992;102(1):109–18.CrossRefPubMed
14.
go back to reference Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24(6):923–36.CrossRefPubMed Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24(6):923–36.CrossRefPubMed
15.
go back to reference Fass R. Proton pump inhibitor failure–what are the therapeutic options? The American journal of gastroenterology 2009, 104 Suppl 2:S33–38. Fass R. Proton pump inhibitor failure–what are the therapeutic options? The American journal of gastroenterology 2009, 104 Suppl 2:S33–38.
16.
go back to reference Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux Disease. J Neurogastroenterol Motil. 2015;21(3):309–19.CrossRefPubMedPubMedCentral Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux Disease. J Neurogastroenterol Motil. 2015;21(3):309–19.CrossRefPubMedPubMedCentral
17.
go back to reference Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864–72.CrossRefPubMedPubMedCentral Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864–72.CrossRefPubMedPubMedCentral
18.
go back to reference Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–20.CrossRefPubMed Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–20.CrossRefPubMed
19.
go back to reference Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.CrossRefPubMed Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.CrossRefPubMed
20.
go back to reference Dent J, Vakil N, Jones R, Bytzer P, Schöning U, Halling K, Junghard O, Lind T. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59(6):714–21.CrossRefPubMed Dent J, Vakil N, Jones R, Bytzer P, Schöning U, Halling K, Junghard O, Lind T. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59(6):714–21.CrossRefPubMed
21.
go back to reference Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D’Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators Alimentary Pharmacology & Therapeutics. 2000;14(10):1249–58.CrossRef Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D’Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators Alimentary Pharmacology & Therapeutics. 2000;14(10):1249–58.CrossRef
22.
go back to reference Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51(5):844–50.CrossRefPubMed Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51(5):844–50.CrossRefPubMed
23.
go back to reference Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93(5):763–7.CrossRefPubMed Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93(5):763–7.CrossRefPubMed
24.
go back to reference Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213–20.CrossRefPubMedPubMedCentral Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213–20.CrossRefPubMedPubMedCentral
25.
go back to reference Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928–37.CrossRefPubMed Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928–37.CrossRefPubMed
Metadata
Title
Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
Authors
Hyun Lim
Jong Kyu Park
Hyunsoo Chung
Si Hyung Lee
Jae Myung Park
Jung Ho Park
Gwang Ha Kim
Sung Kwan Shin
Su Jin Hong
Kwang Jae Lee
Moo In Park
Hye-Kyung Jung
Hyun-Soo Kim
Jae Kyu Sung
Seong Woo Jeon
Suck Chei Choi
Jeong Seop Moon
Nayoung Kim
Jong-Jae Park
Sung Hee Hong
Na Young Kim
Hwoon-Yong Jung
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03087-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.